Pembrolizumab + Lenvatinib + Paclitaxel + Doxorubicin
Phase 3Completed 0 watching 0 views this week📈 Rising
77
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Endometrial Neoplasms
Conditions
Endometrial Neoplasms
Trial Timeline
Jun 11, 2018 → Feb 26, 2025
NCT ID
NCT03517449About Pembrolizumab + Lenvatinib + Paclitaxel + Doxorubicin
Pembrolizumab + Lenvatinib + Paclitaxel + Doxorubicin is a phase 3 stage product being developed by Eisai for Endometrial Neoplasms. The current trial status is completed. This product is registered under clinical trial identifier NCT03517449. Target conditions include Endometrial Neoplasms.
Hype Score Breakdown
Clinical
27
Activity
18
Company
10
Novelty
9
Community
10
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT03517449 | Phase 3 | Completed |
Competing Products
20 competing products in Endometrial Neoplasms